Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Net (2018 - 2025)

Historic Receivables - Net for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $1.3 million.

  • China SXT Pharmaceuticals' Receivables - Net fell 1969.52% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 1969.52%. This contributed to the annual value of $1.3 million for FY2025, which is 5728.14% down from last year.
  • As of Q3 2025, China SXT Pharmaceuticals' Receivables - Net stood at $1.3 million, which was down 1969.52% from $1.3 million recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Receivables - Net peaked at $4.8 million during Q1 2021, and registered a low of $1.3 million during Q1 2025.
  • Its 5-year average for Receivables - Net is $2.8 million, with a median of $3.0 million in 2023.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Receivables - Net tumbled by 6054.89% in 2023 and then soared by 2692.54% in 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Receivables - Net (Quarter) stood at $3.9 million in 2021, then fell by 14.42% to $3.3 million in 2022, then crashed by 60.55% to $1.3 million in 2023, then rose by 26.93% to $1.7 million in 2024, then fell by 19.7% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.3 million for Q1 2025, and $1.7 million during Q3 2024.